Researchers are examining whether GLP-1 receptor agonist drugs, originally developed to treat type 2 diabetes and obesity, may extend human lifespan. These medications work by regulating blood sugar and appetite, and some studies in animals have shown potential longevity benefits. Early human research has indicated cardiovascular advantages and weight loss, though long-term data on lifespan extension in humans remains limited. Several clinical trials are underway to investigate whether these effects translate to increased life expectancy. Scientists caution that more evidence is needed before drawing conclusions about human longevity outcomes.

Next story